Anti-proliferation

Wilfortrine
Catalog No: CFN92105

Wilfortrine can induce liver cancer cell HepG2 apoptosis, but with no effect on the cell cycle, mainly by promoting Bax expression and inhibiting anti-apoptotic protein Bcl-2 expression. The combined treatment using wilfortrine and paclitaxel can inhibit proliferation and invasion of liver cancer cells via down-regulating Bcl-2 and up-regulating Bax, with better efficacy than single use of either drug. Wilfortrine and euonine (40.80 mg/(kg.d) x 4d ip) show marked depressant effects on humoral mediated immunity using the hemolysin reaction as indices.

Juglone
Catalog No: CFN90497

Juglone has anti-inflammatory, and anti-cancer activities, it can significantly inhibit the proliferation and induce the apoptosis of SiHa cells and Caski cells; it prevents high-fat diet-induced liver injury and nerve inflammation in mice through inhibition of inflammatory cytokine secretion, NF-kappa B activation and endotoxin production. Juglone stimulates suicidal erythrocyte death or eryptosis at least in part by upregulation of ceramide abundance, energy depletion and activation of PKC.

Dihydrocucurbitacin B
Catalog No: CFN92140

Dihydrocucurbitacin B has anti-cancer activity, it reduces cell proliferation due to a decrease in the expression of cyclins, mainly cyclin-B1 and disruption of the actin cytoskeleton, arresting B16F10 cells in G2/M phase. Dihydrocucurbitacin B modifies the evolution of the clinical symptoms, reduces the swelling and bone and tissue damage along with the development of the disease, modifies the cell infiltration and the expression of both nitric oxide synthase-2 and cyclooxygenase-2.

Neochamaejasmine A
Catalog No: CFN92151

Neochamaejasmin A can inhibit cellular (3)H-thymidine incorporation (IC 50 12.5 microg/mL) and subsequent proliferation of human prostate cancer LNCaP cells, it blocks cell cycle progression at the G1 phase by activating the p21 protein and ultimately promoting the Fas-caspase 8-caspase 3 apoptotic machinery.

Chamaejasmine
Catalog No: CFN92154

Chamaejasmine could be a candidate drug for osteosarcoma and breast cancer chemoprevention, induces apoptosis in MG63 and HEp-2 cells by Akt inactivation and dephosphorylation of BAD. It inhibits Bcl-2 expression and induces Bax expression to desintegrate the outer mitochondrial membrane and causes cytochrome c release.